COLUMBUS, Ohio - TelAve -- COLUMBUS, Ohio, Genosera Inc., a pre-clinical stage gene therapy company, today announced that it has secured three exclusive licenses from Nationwide Children's Hospital covering seven intellectual property assets. The assets cover a platform of novel dual-gene AAV vectors that couple gene replacement therapy for genetic diseases with a second muscle growth/regeneration therapy to build new muscle mass and strength. This dual-gene AAV therapy approach enhances therapeutic efficacy compared to single gene replacement therapies currently approved for patients.

In pre-clinical studies, the dual gene AAV approach shows not just disease corrective actions but induction of restorative functions when muscle disease has already progressed.  Genosera's platform will change the paradigm for the treatment of genetic muscle diseases, providing the potential to not only stop disease progression but reverse disease in more advanced patients. This approach provides a potential curative therapy, restoring lost muscle mass and strength for neuromuscular disorders, utilizing much lower AAV doses than currently approved therapies.

More on TelAve News

• UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
• Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
• June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
• Phinge Home Of Netverse, Is Actively Investigating The "Model Context Protocol" (MCP) For Infringement Of Its IP From Its June, 2021 Priority Dates
• Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules

Genosera's therapeutic approach will be first assessed in two neuromuscular diseases where the FDA has not approved any therapies: GNE myopathy and LGMD2i (now called LGMDR9).  Patients with GNE myopathy have mutations in the GNE gene, the gene encoding a dual function enzyme that synthesizes the committed steps in sialic acid biosynthesis.  Patients with LGMDR9 have mutations in the FKRP (Fukutin-related protein) gene, which encodes an enzyme required for functional glycosylation of the muscle membrane.

"With our proprietary platform of novel AAV vectors, we have shown dramatic improvements, including reversal of symptoms, in disease models.  We anticipate meeting with the FDA this year to discuss plans for our clinical trials" says Dr. Patricia Beckmann, Chief Executive Officer.

"Further, we believe our dual-gene AAV platform has therapeutic applications in more than two dozen other neuromuscular diseases, as well as some far more common non-genetic conditions such as sarcopenia. By proving safety and efficacy in these first two rare genetic diseases, we can establish Genosera in what should be an expanding portfolio of disease treatments using this new technology."

More on TelAve News

• Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
• Make America French Again Launches National Campaign
• RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area

ABOUT GENOSERA INC.

Founded in 2019, in Columbus, Ohio, Genosera, Inc. is a privately held pre-clinical stage, gene therapy company.  Genosera has developed a pipeline of proprietary innovative dual-gene AAV gene therapy treatments for rare genetic diseases.  Their first-in-class AAV therapies provide a new platform for the treatment of neuromuscular and other disorders. For more information, please visit Genosera's website at www.genosera.com.